In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Achieve Life Sciences (ACHV – Research Report), with a price target of $24.00. The company’s shares opened today at $2.63.
Bernardino covers the Healthcare sector, focusing on stocks such as Geron, Novavax, and Achieve Life Sciences. According to TipRanks, Bernardino has an average return of 18.6% and a 35.23% success rate on recommended stocks.
Currently, the analyst consensus on Achieve Life Sciences is a Strong Buy with an average price target of $21.75.
See today’s best-performing stocks on TipRanks >>
Based on Achieve Life Sciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $13.08 million. In comparison, last year the company had a GAAP net loss of $6.69 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products, cytisine, is a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
Read More on ACHV:
